3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Recurrence
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, Large B-Cell, Diffuse
4
Neoplasms
3
Lymphoma, Non-Hodgkin
3
Lymphoma, B-Cell
3
Multiple Myeloma
2
Lymphoma, Mantle-Cell
2
Leukemia, Myeloid, Acute
2
Breast Neoplasms
2
Plasmacytoma
1
Nasopharyngeal Carcinoma
1
Meningeal Carcinomatosis
1
Lymphoma
1
Liver Neoplasms
1
Leukemia
1
Glioma
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
pembrolizumab
57
Nivolumab
50
Ipilimumab
31
Specimen Handling
23
Magnetic Resonance Spectroscopy
19
Cyclophosphamide
14
Biopsy
11
fludarabine
10
binimetinib
10
Opdualag
10
trametinib
9
relatlimab
9
Radiosurgery
9
CTLA-4 Antigen
9
dabrafenib
8
lifileucel
7
fludarabine phosphate
7
aldesleukin
7
encorafenib
6
Interleukin-2
6
cemiplimab
5
atezolizumab
5
Paclitaxel
5
Blood Specimen Collection
5
X-Rays
4
Taxes
4
Pemetrexed
4
Gemcitabine
4
Cisplatin
4
Carboplatin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Melanoma
×
Immunotherapy, Adoptive
×
90 days
×
Clear all
No trials found.